Insider buying last 90 days
No open-market insider purchases were filed for ANAB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ANAB insider filing, plotted on the chart in Gekko.Open ANAB in Gekko
NASDAQ: ANAB
AnaptysBio (ANAB) Stock Analysis & Forecast
Oct 12 close
$46.04+0.09 (+0.2%)
Gekko Brief
Oct 12 closeAnaptysBio closed at $46.04 on 12 October 2026, +0.2% on the day. The price sits below both the 50-day ($54.19) and 200-day ($54.42) moving averages, inside a 52-week range of $30.27 to $72.36. The GekkoIndex reads 70.8, in the Buying zone, up 0.8 points over five sessions. Gekko Fair Value is $66.63, so the price is 30.9% below it.
The next earnings report is due on 3 November 2026, 22 days away (after close). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 5.5% across the report. Seasonally, the next 20 trading days from this point averaged +5.2% over the last 5 years, rising in 3 of them.
7 firms rate the stock: 7 buy, 0 hold and 0 sell, with a consensus target of $87.25. A typical daily move is about 4.4%, and a typical 20-day move about 11.1%. On the swing-trade checklist, 3 items read supportive and 2 read as a headwind (trend, earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
AnaptysBio price vs fair value
Close $46.04200-day averageGekko Fair Value $66.63
AnaptysBio quick facts
- Market cap
- $1.36B
- P/E ratio
- —
- Forward P/E
- 21
- EPS, TTM
- −$0.96
- Revenue, TTM
- $106.1M
- Profit margin
- 247%
- Dividend yield
- —
- Beta
- 0.45
- Volume
- 371,592 avg 592,633
- 1-year return
- +44.9%
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.1%
- 50-day average
- $54.19
- 200-day average
- $54.42
- Next earnings
- Nov 3 after close
- Shares outstanding
- 29.90M
AnaptysBio swing-trade checklist
AnaptysBio scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $46.04 is below the 50-day ($54.19) and 200-day ($54.42) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
70.8, Buying
Reading 70.8 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
30.9% below
Price is 30.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.2% on average
From this point in the calendar, the next 20 trading days averaged +5.2% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AnaptysBio stock chart and price history
AnaptysBio closed at $46.04 on Oct 12, 2026, +44.9% over the past year, inside a 52-week range of $30.27 to $72.36.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.5%
- 3 months
- −26.3%
- 6 months
- +0.5%
- 1 year
- +44.9%
The full ANAB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ANAB in Gekko
Follow AnaptysBio through every session
Put ANAB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ANAB in GekkoFree for 7 days. No credit card required.
About AnaptysBio
AnaptysBio develops antibody-based therapeutics aimed at autoimmune and inflammatory conditions within the United States. Its pipeline includes rosnilimab, which has completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis by depleting pathogenic T cells, alongside ANB033, a CD122 antagonist being tested in Phase 1b for celiac disease and eosinophilic esophagitis. Other candidates include ANB101, an antibody in Phase 1a that targets plasmacytoid dendritic cells to limit interferon secretion, dostarlimab, a PD-1 antagonist studied across solid tumor types, and imsidolimab, which blocks the interleukin-36 receptor and is in Phase 3 testing for generalized pustular psoriasis.
The company advances many of its antibody programs toward preclinical and clinical milestones through partnerships, holding collaboration agreements with GSK and Vanda.
AnaptysBio is based in San Diego, California, and was incorporated in 2005 under the name Anaptys Biosciences, Inc. before adopting its current name in July 2006. Its shares are listed on the NASDAQ under the ticker ANAB.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- anaptysbio.com
AnaptysBio GekkoIndex: the smart money zone
AnaptysBio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.8, in the Buying zone, up 0.8 points over five sessions.
70.8Buying
Up 0.8 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 67 | +2.8% | +14.0% |
| Accumulation | 115 | +2.3% | +8.2% |
| Neutral | 357 | +0.9% | +3.6% |
| Distribution | 46 | −1.6% | −2.6% |
| Selling | 10 | +4.5% | +6.3% |
Average ANAB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the ANAB price, zone by zone.Track ANAB in Gekko
Is AnaptysBio stock overvalued? Gekko Fair Value
AnaptysBio trades 30.9% below Gekko Fair Value of $66.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what AnaptysBio shares are worth, recalculated every trading day.
$66.63
Gekko Fair Value, Oct 10, 2026
30.9% Undervalued
At the end of Aug 2026 the price was 25.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ANAB in Gekko
AnaptysBio insider and Congress trading
No open-market insider purchases were filed for AnaptysBio, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ANAB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ANAB, plotted on the chart in Gekko.Open ANAB in Gekko
Buybacks
AnaptysBio has been buying back its own shares.
- Latest authorization
- $100.0M, Mar 27, 2026
- Bought back, quarter ended Dec 31, 2025
- $3.38M
- As a share of market cap
- 0.25%
- Trailing four quarters
- $68.63M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold ANAB.
1added2opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
AnaptysBio earnings: next date and track record
AnaptysBio reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- −$1.84
- Revenue estimate
- $25.56M
6 of 8reports beat the EPS estimate
±5.5%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Sep 11, 2026 | −$0.46 est −$0.46 | $13.34M est $14.06M | −1.9% |
| May 12, 2026 | −$1.84 est −$1.07 | $25.56M est $18.86M | −7.7% |
| Mar 3, 2026 | $1.58 est $0.93 | $108.2M est $87.04M | +10.3% |
| Nov 4, 2025 | $0.52 est −$1.06 | $76.32M est $87.09M | −0.1% |
| Aug 7, 2025 | −$1.34 est −$1.50 | $22.26M est $11.68M | −6.7% |
| May 5, 2025 | −$1.28 est −$1.30 | $27.77M est $15.27M | −5.0% |
| Feb 27, 2025 | −$0.72 est −$1.55 | $43.11M est $7.78M | −1.1% |
| Nov 5, 2024 | −$1.14 est −$1.65 | $30.02M est $8.21M | +11.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AnaptysBio stock forecast and analyst price targets
Analysts’ average 12-month price target for AnaptysBio is $87.25, +89.5% from the last close, from 7 firms rating the stock in the last 90 days.
$87.25consensus 12-month target, +89.5% from the last close
Now $46.04Avg $87.25
Low $60High $95
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | H.C. Wainwright | $95 | +106.3% |
| Sep 30 | J.P. Morgan | $60 | +30.3% |
| Sep 23 | Leerink Partners | $81 | +75.9% |
| Sep 22 | H.C. Wainwright | $95 | +106.3% |
| Sep 22 | Barclays | $75 | +62.9% |
+14.0%average 20-day move after past Buying readings
+5.2%average move over the next 20 trading days in the last 5 years
±4.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AnaptysBio seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, AnaptysBio averaged +5.2% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.5% | 3 of 5 |
| Next 10 trading days | +4.0% | 4 of 5 |
| Next 15 trading days | −1.0% | 3 of 5 |
| Next 20 trading days | +5.2% | 3 of 5 |
| Next 30 trading days | −4.7% | 3 of 5 |
For scale, ANAB’s typical 20-trading-day move in either direction is about 11.1%.
AnaptysBio market cap and key statistics
AnaptysBio’s market cap is $1.36B and revenue of $106.1M over the last twelve months.
Valuation
- Market cap
- $1.36B
- Forward P/E
- 21
- EPS, TTM
- −$0.96
- Gekko Fair Value
- $66.63
Trading
- Volume
- 371,592
- Avg volume, 20 days
- 592,633
- 52-week high
- $72.36
- 52-week low
- $30.27
- Shares outstanding
- 29.90M
Financials
- Revenue, TTM
- $106.1M
- Profit margin
- 247%
- Return on equity
- -114.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.45
- Typical daily move
- ±4.4%
- Typical 20-day move
- ±11.1%
AnaptysBio stock news this week
Coverage of AnaptysBio this week reads positive: 3 positive, 0 neutral and 1 negative headlines.
- AnaptysBio (ANAB) Slides As Royalty And Delaware Debate Tests Whether Shares Are A BargainSimply Wall Street, Oct 11
- AnaptysBio earnings beat by $5.58, revenue topped estimatesInvesting.com UK, Oct 10
- AnaptysBio Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 7
- AnaptysBio, Inc. (AN6.F) Analyst Insights, Price Targets & RecommendationsYahoo! Finance Canada, Oct 5
AnaptysBio peers
AnaptysBio’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
AnaptysBio stock FAQ
What is AnaptysBio’s market cap?
AnaptysBio’s market cap is $1.36B at the Oct 12, 2026 close of $46.04, with 29.90M shares outstanding.
What is the AnaptysBio stock forecast?
The consensus analyst 12-month price target for AnaptysBio is $87.25, +89.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is AnaptysBio stock overvalued or undervalued?
On Gekko’s estimate AnaptysBio is undervalued: the Oct 12, 2026 close of $46.04 is 30.9% below Gekko Fair Value of $66.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AnaptysBio report earnings next?
AnaptysBio is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of −$1.84 per share on revenue of $25.56M. AnaptysBio beat the earnings estimate in 6 of its last 8 reports, moving 5.5% on average across the report.
What is AnaptysBio’s 52-week high and low?
AnaptysBio’s 52-week high is $72.36 and its 52-week low is $30.27; it closed at $46.04 on Oct 12, 2026, +44.9% over the past year.
Is AnaptysBio stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AnaptysBio the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.